You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Paraproteinemias

Showing 1 - 25 of 87
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Tumors, Tumor, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 11, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +8 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 13, 2022

Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Mar 4, 2022

Monoclonal Gammopathies, Multiple Myeloma, M-protein Trial in Guangzhou (Observational studies, no intervention)

Recruiting
  • Monoclonal Gammopathies
  • +2 more
  • Observational studies, no intervention
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Jan 6, 2023

Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Cryoglobulinemic Vasculitis Trial (Isatuximab Injection)

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Isatuximab Injection
  • (no location specified)
Oct 28, 2021

Quality of Life in Asymptomatic Monoclonal Gammopathies

Recruiting
  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Plasma Cell Myeloma
  • Quality-of-Life Assessment
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

The Indiana Myeloma Registry

Recruiting
  • Plasma Cell Dyscrasias
  • This is a non-interventional trial
  • Indianapolis, Indiana
    Indiana University Simon Cancer Center
Mar 2, 2022

Monoclonal Gammopathy Trial in New York, Philadelphia (Isatuximab)

Recruiting
  • Monoclonal Gammopathy
  • Boston, Massachusetts
  • +1 more
Nov 16, 2022

Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)

Not yet recruiting
  • Lymphoma
  • +2 more
  • Web Application
  • San Francisco, California
    University of California, San Francisco
Oct 4, 2022

Two Biologically and Clinically Distinct Entities: Progressive

Recruiting
  • Multiple Myeloma
  • +2 more
    • Miami, Florida
      University of Miami Hospitals
    Jun 7, 2022

    Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Bortezomib, Cyclophosphamide)

    Not yet recruiting
    • Multiple Myeloma
    • +7 more
    • Athens, Greece
    • +5 more
    Mar 28, 2022

    Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Pomalidomide, Dexamethasone)

    Not yet recruiting
    • Multiple Myeloma
    • +7 more
    • Athens, Greece
    • +5 more
    Mar 17, 2022

    Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in Cleveland (Multiple

    Not yet recruiting
    • Multiple Myeloma
    • +2 more
    • Multiple Myeloma M-Protein Analysis
    • Multiple Myeloma Knowledge Questionnaires
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
    Apr 26, 2023

    Study in Monoclonal Gammopathy of Undetermined Significance

    Not yet recruiting
    • MGUS
      • Oxford, Oxfordshire, United Kingdom
        Secure Study
      Sep 9, 2022

      Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

      Active, not recruiting
      • Multiple Myeloma
      • +19 more
      • CYNK-001
      • Denver, Colorado
      • +8 more
      May 24, 2022

      Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM) Trial in Rochester (Curcumin plus Piperine)

      Recruiting
      • Prostate Cancer
      • +3 more
      • Curcumin plus Piperine
      • Rochester, New York
        University of Rochester
      Jun 17, 2022

      IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy Trial in Atlanta (Rifaximin)

      Recruiting
      • IgA Monoclonal Gammopathy
      • +8 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Oct 18, 2021

      Multicenter Case Series

      Recruiting
      • Monoclonal Gammopathy of Renal Significance
        • San Fermo Della Battaglia, Como, Italy
        • +7 more
        Jan 23, 2023

        A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

        Recruiting
        • Multiple Myeloma
        • +11 more
        • No intervention
        • Beijing, China
          Peking University First Hospital
        Apr 21, 2022

        Natural History of MGUS in Patients Undergoing Weight Reduction

        Recruiting
        • Monoclonal Gammopathy of Undetermined Significance
          • Indianapolis, Indiana
            Indiana University Simon Cancer Center
          Jun 23, 2021

          Progression to Myeloma in Asymptomatic Monoclonal Gammopathies

          Recruiting
          • Monoclonal Gammopathy of Undetermined Significance
          • Smoldering Plasma Cell Myeloma
          • Biospecimen Collection
          • Laboratory Biomarker Analysis
          • Houston, Texas
            M D Anderson Cancer Center
          Oct 4, 2021

          Multiple Myeloma, Amyloidosis, Cryoglobulinemia Trial in Chapel Hill

          Recruiting
          • Multiple Myeloma
          • +8 more
            • Chapel Hill, North Carolina
              North Carolina Cancer Hospital
            Nov 30, 2021

            Monoclonal Gammopathy, Smoldering Myeloma, Myeloma Trial in Cleveland (DKK1)

            Not yet recruiting
            • Monoclonal Gammopathy
            • +2 more
            • DKK1
            • Cleveland, Ohio
            • +1 more
            Nov 29, 2021

            Monoclonal Gammopathy of Undetermined Significance Trial in Reykjavík (Clinical follow-up 1, Mental Health and Quality of Life

            Active, not recruiting
            • Monoclonal Gammopathy of Undetermined Significance
            • Clinical follow-up 1
            • +5 more
            • Reykjavík, Iceland
              University of Iceland
            Feb 28, 2022

            MGUS, SMM, and MM Patient Experience With Coronavirus 19 Survey

            Recruiting
            • Multiple Myeloma
            • +3 more
            • Questionnaire
            • Lehi, Utah
              HealthTree.org (Online)
            Aug 2, 2021